Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

  • AJOVY® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1
  • Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed
  • Full data presented as a late breaker at European Headache Congress (EHC) 4-7 December in Rotterdam, Netherlands

TEL AVIV, Israel, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) presented positive data from its Phase 3 SPACE study evaluating the efficacy and safety of AJOVY® (fremanezumab) for the prevention of episodic migraine in children and adolescent patients aged 6-17 years.1 The trial showed statistically significant superior efficacy compared to placebo over 12 weeks with a favourable safety profile1 consistent with that observed in the adult population.

Migraine is common among children, with an overall estimated prevalence of 7.7%.2 The prevalence increases from 5% among children aged 5 to 10 years-old to approximately 15% among adolescents.2 Migraine can cause significant disability in children and adolescents, leading to absence from school, impaired educational performance and missed social activities.2

One of the lead investigators of the trial, Professor Patricia Pozo-Rosich, Headache Unit and Research Group, Head of Section Neurology Department at Vall d’Hebron Hospital and Research Institute, Barcelona said “This is an important milestone for clinicians and young patients living with episodic migraine who currently have little treatment options available to them. This is the first Phase 3 trial of a CGRP-pathway treatment that has shown statistically superior efficacy with favourable safety and tolerability for the prevention of episodic migraine in children and adolescents.”

SPACE is a multicentre, double-blind study evaluating the efficacy and safety of fremanezumab in 237 children and adolescents with episodic migraine aged 6-17 years. The pediatric study participants had been diagnosed with migraine for 6 months or more, with a history of less than 14 headache days a month. The trial included subgroup analyses by age (6 -11 years and 12 -17 years) and by sex.1

Highlights from the SPACE data showed that over 3 months fremanezumab achieved:1

  • Significant reduction in monthly migraine days (MMD) vs placebo (-2.5 vs -1.4; p=0.0210)
  • Significant reduction in monthly headache days (MHD) vs placebo (-2.6 vs -1.5; p=0.0172)
  • Significantly higher number of children achieving a 50% response rate vs placebo (47.2% vs 27.0%; p=0.0016)
  • Benefits were similar in both the age subgroups and between boys and girls

Fremanezumab also demonstrated a favourable safety profile, and was well tolerated with no safety signals:1  

  • Proportion of children reporting ≥1 adverse events (AEs) was similar between the treatment group vs placebo (55% vs 49%)
  • Proportion of patients with serious adverse events (SAEs) and AEs leading to treatment discontinuation was low at ≤3% and ≤1% respectively

“Over the last 30 years, the incidence of childhood migraine has increased but there has been little innovation in licenced treatments to manage this debilitating condition in children.” said Eric A. Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer, Teva Pharmaceuticals. 'We’ve already seen the benefits of AJOVY in adults and the SPACE trial has confirmed that children with episodic migraine can also benefit from AJOVY. This is a significant step forward for the care of migraine in children and adolescents who are having to live with this high burden.”

Teva continues to study the impact of fremanezumab in pediatric patients with chronic migraine and its long-term safety.

About SPACE

SPACE is a multicentre, randomised, double-blind, placebo-controlled, parallel-group study comparing the efficacy, safety, and tolerability of subcutaneous administration of fremanezumab versus placebo over a 12 week period for the preventive treatment of episodic migraine in 237 pediatric patients aged 6 to 17 years.  

About AJOVY®

AJOVY® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled syringe or, in some countries, in a pre-filled pen. Two dosing options are available: 225 mg once monthly administered as one subcutaneous injection (monthly dosing), or 675 mg every three months (quarterly dosing), which is administered as three subcutaneous injections. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescents ; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; and other factors discussed in this press release, in our quarterly report on Form 10-Q for the third quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned 'Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

1 Hershey, A., et al. Efficacy and Safety of Fremanezumab for the Preventive Treatment of Episodic Migraine in Children and Adolescents: a Phase 3, Randomised, Double-Blind, Placebo-Controlled Study. Presented at European Headache Congress (EHC); 4-7 December 2024, Rotterdam. ePoster LP036.

2 Pediatric Migraine, An Update. Greene, Kaitlin. et al; Neurology clinics, Volume 37, Issue 4, 815-833. August 31, 2019. https://doi.org/10.1016/j.ncl.2019.07.009

IR Contacts Chris Stevo+1 (339) 213-3999
  Yael Ashman+972 (3) 914 8262
  Sanjeev Sharma+1 (973) 658 2700 
Media Contacts Kelley Dougherty+1 (973) 832-2810
  Eden Klein+972 (3) 906 2645  

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial


THỦ THUẬT HAY

Nhanh tay nhận bản quyền phần mềm CyberLink ColorDirector 5 hoàn toàn miễn phí

CyberLink ColorDirector 5 là công cụ chỉnh sửa màu sắc chuyên nghiệp cho phép bạn điều chỉnh màu sắc của các chi tiết trong video.

Cách kích hoạt giao diện trình duyệt Chrome mới trên iOS

Bằng cách kích hoạt giao diện mới của trình duyệt Chrome trên iOS, người dùng sẽ có được một giao diện mới đẹp mắt, hiện đại và dễ dàng thao tác hơn khi so với giao diện cũ. Bên cạnh đó, nhờ giao diện mới mà người dùng

Cách di chuyển nhanh một hàng trong Words 2013

Bạn đã bao giờ căng mắt tìm trong bảng cho ra những hàng cần sắp xếp lại vị trí? Chỉ với những thao tác đơn giản sử dụng tổ hợp phím tắt là bạn có thể di chuyển các hàng lên hoặc xuống trong bảng một cách dễ dàng theo

5 cách chuyển dữ liệu Samsung sang thiết bị khác dễ dàng

Khi bạn muốn chuyển đổi từ điện thoại Samsung cũ sang một thiết bị mới, việc chuyển dữ liệu là điều cần thiết để bạn không bị mất đi các thông tin quan trọng như danh bạ, hình ảnh, tin nhắn, tài liệu, và các ứng dụng

5 cách khắc phục lỗi mất phím volume trên iPhone đơn giản nhất

Lỗi mất phím trên iPhone không còn xa lạ với những người sử dụng dòng điện thoại này nhưng không phải ai cũng có thể khắc phục và lỗi này ảnh hưởng đến sự trải nghiệm khi sử dụng, gây sự khó chịu đến người dùng.

ĐÁNH GIÁ NHANH

Đánh giá CPU Core i7-8700K giá khoảng 9,75 triệu đồng

Về cơ bản, thiết kế Core i7-8700K vẫn áp dụng quy trình sản xuất 14nm tương tự chip i7-7700K nhưng tối ưu hơn về hiệu suất tính toán trên mỗi watt điện năng tiêu thụ.

Trên tay Huawei Nova 8 SE: Dimensity 720, 4 camera sau 64MP, sạc nhanh 66W

Huawei Nova 8 SE có thiết kế khá giống với iPhone 12 của Apple nhưng nó được trang bị chip MediaTek và giao diện người dùng EMUI.

Honda PCX 2018: Xe ga phổ thông có tư thế ngồi lái thoải mái nhất hiện nay

Được biết đến như một mẫu xe tay ga có ngoại hình to lớn với ngôn ngữ thiết kế cũng khá đặc biệt nhưng được cho là khá 'già' và chỉ phù hợp cho những đối tượng trung niên. ở mẫu Honda PCX 2018, tuy chiếc xe cũng sở hữu